EP3200776A1 — Beta lactamase inhibitors
Assigned to Oxford University Innovation Ltd · Expires 2017-08-09 · 9y expired
What this patent protects
A compound which is a thienolate of formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R 1 , R 3 , Ring A1, n and Ring A2 are as defined herein, are found to be useful in inhibiting metallo-beta-lactamase and therefore in potentiating the activity of beta lact…
USPTO Abstract
A compound which is a thienolate of formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R 1 , R 3 , Ring A1, n and Ring A2 are as defined herein, are found to be useful in inhibiting metallo-beta-lactamase and therefore in potentiating the activity of beta lactamase antibiotics. The compound can be used alone or in combination with a rhodanine of formula (II) or a pharmaceutically acceptable salt thereof: (II) wherein R 3 , Ring A1, n, Ring A2, L and Ring B are as defined herein. Treatment or prevention of bacterial infection in combination with beta-lactam antibiotic agents is also provided.
Drugs covered by this patent
- Col-Probenecid (probenecid) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.